Literature DB >> 9894722

In vitro cytokine-primed leukaemia cells induce in vivo T cell responsiveness in chronic myeloid leukaemia.

S H Lim1, S Coleman, R Bailey-Wood.   

Abstract

We previously showed that in chronic myeloid leukaemia (CML), it is possible to induce costimulatory molecules, CD80/CD86, on leukaemia cells by culturing adherent peripheral blood mononuclear cells from these patients with IL-4 and GM-CSF. In addition to the expression of CD80/CD86 molecules, some of the leukaemia cells also expressed the dendritic cell marker, CD1a. When these leukaemia cells were used in mixed lymphocyte leukaemia reactions, they mediated autologous T cell proliferation not seen when fresh leukaemia cells were used as the stimulator cells. In this study, we showed that reinfusion of these immunogenic leukaemia cells to the autologous hosts resulted in priming in vivo of T cells so that they could respond to subsequent rechallenge in vitro with fresh autologous leukaemia cells. Although cytotoxic T cells against leukaemia cells were not demonstrated, these T cells could proliferate and produce interferon-y when cocultured in vitro with the leukaemia cells. Our findings therefore provide further evidence for the immunogenicity of these cultured leukaemia cells in CML.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9894722     DOI: 10.1038/sj.bmt.1701511

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

1.  Clinical reagents of GM-CSF and IFN-α induce the generation of functional chronic myeloid leukemia dendritic cells in vitro.

Authors:  Kaizhi Weng; Xiaobao Xie; Guoqiang Qiu; Weiying Gu
Journal:  Cytotechnology       Date:  2011-09-22       Impact factor: 2.058

Review 2.  Immunotherapeutic strategies in chronic myeloid leukemia.

Authors:  Richard E Clark
Journal:  Curr Hematol Malig Rep       Date:  2007-05       Impact factor: 4.213

3.  Expression of testicular genes in haematological malignancies.

Authors:  S H Lim; S Austin; E Owen-Jones; L Robinson
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.